<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Secondary central nervous system lymphoma: Clinical features and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Secondary central nervous system lymphoma: Clinical features and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Secondary central nervous system lymphoma: Clinical features and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joachim M Baehring, MD, DSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fred H Hochberg, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Systemic non-Hodgkin lymphoma (NHL) may involve the nervous system at every level, including peripheral nerve, spinal nerve root, spinal cord, meninges, and brain. Such involvement may include direct invasion or compression of these structures, as well as paraneoplastic effects of NHL. Whereas involvement of the central nervous system (CNS) complicates the course of a substantial minority of patients, peripheral nervous system (PNS) involvement is rare. (See  <a class="medical medical_review" href="/z/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system"</a>.)</p><p>NHL can involve the CNS either as the sole area of disease (ie, primary CNS lymphoma [PCNSL]) or as secondary spread of systemic disease. Secondary involvement of the CNS by NHL can present in many ways, and rapid control of CNS involvement is necessary to prevent neurologic morbidity and preserve quality of life. As such, clinicians must keep this entity high on their differential diagnosis in patients with NHL presenting with neurologic complaints. The most common manifestations of NHL involvement of the CNS include leptomeningeal disease and parenchymal brain involvement.</p><p>The clinical features and diagnosis of secondary CNS lymphoma will be discussed here. Treatment of secondary CNS lymphoma and PCNSL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/89417.html" rel="external">"Secondary central nervous system lymphoma: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/4693.html" rel="external">"Primary central nervous system lymphoma: Clinical features, diagnosis, and extent of disease evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/4706.html" rel="external">"Primary central nervous system lymphoma: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/4751.html" rel="external">"HIV-related lymphomas: Primary central nervous system lymphoma"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>There are limited data regarding the cellular or molecular interactions that facilitate trafficking of lymphoma cells to the CNS. Lymphoma cells are thought to enter the CNS by hematogenous spread, direct extension from adjacent bone marrow infiltration, or centripetal growth along neurovascular bundles. It has also been hypothesized that lymphoma cells could spread from retroperitoneal lymph nodes or bone marrow to the leptomeninges via the intervertebral venous plexus [<a href="#rid1">1</a>], although confirmatory evidence for this mode of spread is lacking.</p><p>Most episodes of CNS involvement by non-Hodgkin lymphoma (NHL) occur in the setting of relapsed disease [<a href="#rid2">2</a>]; however, a considerable percentage may have had subclinical CNS involvement at the time of diagnosis. This is suggested by the high rate of CNS involvement within six months of initial therapy in many patients with aggressive NHL [<a href="#rid3">3</a>]. In addition, late CNS recurrences of NHL may represent second primary tumors. Support for this hypothesis comes from molecular studies in which immunoglobulin heavy chain (IgH) gene rearrangement analysis suggested a separate clonal origin for some CNS tumors arising more than three years after the initial diagnosis of NHL [<a href="#rid4">4</a>].</p><p>Most data on the mechanism of spread of NHL to the CNS come from studies of varieties of T cell lymphoma with an unusually high rate of extranodal involvement. These malignancies typically express CD56, which is also known as the neural cell adhesion molecule (NCAM) [<a href="#rid5">5</a>]. NCAM is a member of the immunoglobulin superfamily of cell adhesion molecules; it exhibits homophilic (like-to-like) binding, which allows NCAM molecules to facilitate adhesion among neighboring cells with surface NCAM expression. NCAM is naturally expressed on multiple cell types in the brain, spinal cord, muscle, and hematopoietic tissue [<a href="#rid5">5</a>]. As such, expression of NCAM may allow these tumor cells to interact with cells in the CNS that also express NCAM. In a series of 46 patients with T cell lymphoma evaluated during a 12-year period, 24 percent of the tumors were NCAM-positive [<a href="#rid6">6</a>]. Of these, 36 percent had CNS involvement, compared with 3 percent of NCAM-negative tumors. NCAM-positive tumors had a clear predilection for widespread extranodal involvement, with a median survival less than half that of NCAM-negative tumors. (See  <a class="medical medical_review" href="/z/d/html/3983.html" rel="external">"Leukocyte-endothelial adhesion in the pathogenesis of inflammation"</a>.)</p><p>Clues surrounding the migration of NHL to the CNS may also be found by examining the molecular phenotype of normal lymphocytes that migrate to the CNS and how this phenotype differs from that of lymphocytes that do not travel to the CNS [<a href="#rid7">7</a>]. As an example, a study of T lymphocyte trafficking into the subarachnoid space of healthy individuals found that P- and E-selectin expression on endothelial cells in the CNS may be a crucial discrepancy between these lymphocytes and others [<a href="#rid8">8</a>]. Whether these data also apply to neoplastic lymphocytes traveling to the healthy CNS is unclear.</p><p>B lymphocytes may also enter the brain even under normal circumstances, although the molecular mechanisms that make this possible have not been fully described [<a href="#rid9">9</a>].</p><p>In primary CNS lymphoma (PCNSL), a B cell-attracting chemokine, CXCL13, may play an important role in lymphocyte retention within the CNS [<a href="#rid10">10</a>]. A subset of patients with PCNSL may have occult systemic disease at presentation that eludes detection by routine staging techniques [<a href="#rid11">11</a>]. This patient population may provide insight into the mechanisms by which lymphoma cells home to the CNS. Exome sequencing of PCNSL has revealed frequent mutations in genes known to play a role in CNS development, possibly pointing to mechanisms of CNS tropism [<a href="#rid12">12</a>]. Other research in PCNSL models suggests that faulty germinal center reactions may increase B cell receptor reactivity, particularly for proteins expressed in the CNS, and thereby foster tumor cell survival within the CNS [<a href="#rid13">13</a>].</p><p>Another possible homing mechanism is stimulation by posttranslationally modified autoantigens. In one study, two-thirds of patients with PCNSL expressed B cell receptors specific for two autoantigens predominantly expressed in the CNS (neurabin I and atypically hyper-N-glycosylated SAMD14) [<a href="#rid14">14</a>]. By contrast, autoantibodies targeting SAMD14 and neurabin I were not present in patients with secondary CNS involvement by systemic diffuse large B cell lymphoma (DLBCL).</p><p class="headingAnchor" id="H171056704"><span class="h1">INCIDENCE AND RISK FACTORS</span><span class="headingEndMark"> — </span>CNS disease is found in a minority of patients at the time of non-Hodgkin lymphoma (NHL) diagnosis, the exact percentage of which differs by histologic subtype. The majority of cases of CNS involvement by NHL occur in the setting of relapsed disease. Nearly half of the patients have concurrent systemic relapse [<a href="#rid15">15</a>].</p><p>The frequency of CNS involvement in systemic NHL varies depending at least partially upon the aggressiveness of the NHL subtype. Approximately 2 to 10 percent of patients with aggressive subtypes of systemic NHL (eg, diffuse large B cell lymphoma [DLBCL]) will experience direct involvement of the CNS at some time during their course [<a href="#rid3">3,16-22</a>]. The incidence is much higher in highly aggressive NHL (eg, Burkitt lymphoma, lymphoblastic lymphoma/leukemia) and lower in indolent NHL (eg, follicular lymphoma). In a contemporary multicenter study spanning a decade, the incidence of CNS dissemination by Burkitt lymphoma was 19 percent [<a href="#rid23">23</a>]. Peripheral nervous system (PNS) involvement by lymphoma is rare.</p><p>It is unknown whether the risk of CNS relapse has changed as initial treatment of these diseases has evolved. Several retrospective studies have suggested that the incidence may be lower among patients with B cell NHL treated with rituximab-containing therapy [<a href="#rid24">24,25</a>] or etoposide-containing therapy [<a href="#rid22">22,26</a>]. Other studies have found no difference in the incidence of CNS relapse in the pre- versus post-rituximab era [<a href="#rid27">27,28</a>].</p><p>In addition to histologic subtype, risk factors for invasion of the neuraxis by NHL include the primary site of disease and the extent of bulky disease  (<a class="graphic graphic_table graphicRef54470" href="/z/d/graphic/54470.html" rel="external">table 1</a>). These issues are discussed in the following sections.</p><p class="headingAnchor" id="H4"><span class="h2">Histologic subtype</span><span class="headingEndMark"> — </span>The histologic subtype of lymphoma is the major risk factor for nervous system involvement [<a href="#rid17">17,20</a>]. The incidence of CNS relapse without CNS prophylaxis ranges from less than 3 percent in patients with indolent subtypes of lymphoma to 50 percent in some patients with highly aggressive NHL subtypes, such as Burkitt lymphoma or lymphoblastic lymphoma [<a href="#rid29">29</a>]. Although histologic subtype is an indicator of risk for CNS involvement, nearly every lymphoma subtype has been reported to invade the nervous system. (See  <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>A single-center retrospective study of 2514 consecutive patients with newly diagnosed NHL with a median follow-up of 94 months reported that 106 patients (4.2 percent) developed CNS disease either during (36 patients) or after (70 patients) primary treatment, with a median time to diagnosis of CNS involvement of 10 months [<a href="#rid20">20</a>]. Of the 1163 patients with low-grade histology, 33 (2.8 percent) developed CNS involvement  (<a class="graphic graphic_table graphicRef59978" href="/z/d/graphic/59978.html" rel="external">table 2</a>). Of the 1220 patients with aggressive NHL, 53 (4.3 percent) developed CNS involvement, 35 of which occurred during the first year after NHL diagnosis. This rate has never been confirmed in a prospectively gathered cohort.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 498 patients with NHL, 30 developed secondary CNS disease [<a href="#rid17">17</a>]. Twenty-six of the 30 had aggressive or highly aggressive disease. As examples, the risk of CNS recurrence was 23 percent for lymphoblastic lymphoma and only 1.4 percent for those with indolent lymphoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mantle cell lymphoma (MCL), which can behave as either an indolent or an aggressive NHL variant, has an unusually high risk of CNS involvement, approaching 4 percent [<a href="#rid30">30,31</a>]. An important factor may be the increased frequency of advanced disease at the time of diagnosis of MCL, when compared with other indolent NHL variants. (See <a class="local">'Risk scores'</a> below and  <a class="medical medical_review" href="/z/d/html/4702.html" rel="external">"Mantle cell lymphoma: Epidemiology, pathobiology, clinical manifestations, diagnosis, and prognosis", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A single-institution retrospective review of 250 patients with peripheral T cell NHL (PTCL) from the United States reported a CNS relapse rate of 2.4 percent [<a href="#rid32">32</a>]. Another retrospective analysis of 600 PTCL patients revealed a cumulative CNS relapse rate of 2.1 percent at five years [<a href="#rid33">33</a>]. In comparison, a retrospective study of 228 patients from Korea with primary NK/T cell NHL reported a rate of CNS involvement of 8.8 percent [<a href="#rid34">34</a>]. The higher rate in this population likely reflects the predilection of NK/T cell lymphoma for involvement of the hard palate and nose, with venous drainage to the cavernous sinuses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although the indolent T cell lymphoma mycosis fungoides (MF) primarily involves the skin, autopsy and clinical studies have demonstrated nervous system involvement indistinguishable from that caused by other lymphomas [<a href="#rid35">35,36</a>]. (See  <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides", section on 'Clinical features'</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Primary site</span><span class="headingEndMark"> — </span>While it is clear that the rate of CNS involvement differs based upon the primary site of disease, there is controversy regarding which primary sites of disease should be considered high risk. Most studies have noted a high rate of CNS involvement with lymphomatous involvement of the testes [<a href="#rid22">22,37,38</a>]. In addition, an increased risk of CNS disease has been associated with lymphomatous involvement of the paranasal sinuses [<a href="#rid22">22,39,40</a>] and retroperitoneal lymph nodes [<a href="#rid39">39,41</a>]. An association between CNS involvement and other sites of primary NHL is more controversial.</p><p class="bulletIndent1"><span class="glyph">●</span>An analysis of CNS relapse among 1386 patients with newly diagnosed aggressive NHL treated on prospective trials of chemotherapy in Germany reported that 2.2 percent of patients developed CNS relapse [<a href="#rid22">22</a>]. When compared with patients without these sites of involvement, the probability of developing CNS relapse by six years was increased in patients with involvement of the testes (22 versus 2 percent), orbit/sinus (33 versus 2 percent), liver, bladder, adrenals, or kidney. Unlike other studies, this analysis did not find an increased risk associated with bone marrow involvement. While these primary sites of disease were associated with increased risk of subsequent CNS involvement, only elevated serum lactate dehydrogenase (LDH) and involvement of &gt;1 extranodal site were independent risk factors for CNS involvement on multivariate analysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several retrospective studies have noted an increased risk of CNS disease among patients with bone and bone marrow involvement [<a href="#rid18">18,42,43</a>], while others have not [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several studies have noted an increased risk of CNS relapse among patients with primary testicular lymphoma in both young and older adults [<a href="#rid22">22,37,38,44</a>]. As an example, one review found that 13 of 62 such patients (21 percent) experienced CNS relapse, with 8 of the 13 recurrences isolated to the CNS [<a href="#rid37">37</a>]. Late CNS recurrences were also common, with one patient developing CNS recurrence 13 years after entering remission.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of 87 patients with NHL involving the kidneys identified through a multinational lymphoma study group member survey, the proportion with CNS dissemination was 13 percent (two patients at initial diagnosis, nine at relapse after a median follow-up of 22 months) [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several studies have noted an increased rate of CNS involvement in patients with primary breast lymphoma [<a href="#rid46">46-50</a>] and primary mediastinal large B cell lymphoma [<a href="#rid51">51</a>]. Whether this risk exceeds the risk in the entire DLBCL population is uncertain [<a href="#rid52">52-54</a>]. An international retrospective analysis of 204 patients with primary DLBCL of the breast, only 8 of whom received CNS prophylaxis, reported CNS relapse in 5 percent after a median follow-up of 5.5 years [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although primary cutaneous lymphoma is often cited as a risk factor for CNS recurrence, this did not appear to be the case in a large series [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravascular lymphoma is an uncommon form of DLBCL with a rate of CNS involvement approaching 40 percent. (See  <a class="medical medical_review" href="/z/d/html/4738.html" rel="external">"Intravascular large B cell lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H2613766159"><span class="h2">Molecular genetic risk factors</span><span class="headingEndMark"> — </span>"Double-" or "triple-hit" high-grade lymphomas harboring translocations of <em>MYC</em> and <em>BCL2</em> or <em>BCL6 </em>carry a high risk of CNS dissemination. In one study, the cumulative risk at three years was 13 percent [<a href="#rid57">57</a>]. An increased risk is also observed in double-expressing lymphoma (<em>MYC</em> and <em>BCL2</em> expression in the absence of translocations), especially within the ABC subtype (cumulative risk of 10 percent at two years for all double expressers, 15 percent for ABC subtype) [<a href="#rid58">58</a>]. Recognition of these biologic risk factors has led to the use of treatment protocols that include CNS-penetrating drugs. (See  <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'Clinical and laboratory'</a>.)</p><p>Other molecular alterations may predict risk of CNS relapse. In one trial cohort of patients with DLBCL, cyclin-dependent kinase inhibitor 2A (<em>CDKN2A</em>) was the most commonly altered gene in patients who developed CNS relapse (mostly homozygous deletions) [<a href="#rid59">59</a>]. On multivariate analysis, <em>CDKN2A</em> gene alterations were associated with higher risk for CNS relapse.</p><p>Genetic subtypes defined by next-generation sequencing are also under investigation as predictors of CNS relapse. In one study, a high-risk subtype was characterized by <em>MYD88</em> and <em>CD79B</em> alterations, similar to those seen in primary CNS lymphoma (PCNSL) [<a href="#rid60">60,61</a>]. A second high-risk subtype contained <em>MYC </em>translocations and <em>BCL2 </em>or tumor protein p53 (<em>TP53</em>) variants.</p><p class="headingAnchor" id="H6"><span class="h2">Risk scores</span><span class="headingEndMark"> — </span>In patients with DLBCL, the most widely used predictive model for risk of CNS relapse is the CNS International Prognostic Index (CNS-IPI) prognostic score, which was derived and validated from combined data of the British Columbia Cancer Agency and the German High-Grade Lymphoma Study Group [<a href="#rid62">62-64</a>]. The CNS-IPI uses IPI risk factors (age &gt;60, LDH greater than normal, performance status &gt;1, stage 3 or 4 disease, and &gt;1 extranodal site of involvement), as well as the presence of renal or adrenal involvement with lymphoma, to generate a prognostic score with the following risk tiers [<a href="#rid62">62-64</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with four to six risk factors had a two-year CNS relapse risk of 10.2 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with two to three risk factors had a two-year CNS relapse risk of 3.4 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with zero to one risk factors had a two-year CNS relapse risk of 0.6 percent</p><p></p><p>A limitation of the CNS-IPI is that it may not adequately account for anatomic and molecular factors associated with elevated risk of CNS relapse, independent of other clinical risk factors. Aside from renal or adrenal involvement, which is included in the CNS-IPI, DLBCL involvement of the testes and breast also confers increased risk of CNS relapse [<a href="#rid37">37,65-69</a>]. Other potentially high-risk sites include uterus, orbit, retroperitoneum, and bone marrow [<a href="#rid20">20,70,71</a>]. (See <a class="local">'Primary site'</a> above.)</p><p>The combination of CNS-IPI and cell of origin (COO) information (but not <em>BCL2</em>/<em>MYC</em> dual expression status) improved CNS relapse prediction in a retrospective analysis of the large patient cohort enrolled in the GOYA trial [<a href="#rid59">59</a>]. High CNS-IPI score and activated B cell (ABC) type/unknown COO identified a subgroup of patients at high risk of CNS dissemination (15.2 percent at two years versus 0.5 percent for low CNS-IPI score and known non-ABC subtype) [<a href="#rid59">59</a>].</p><p>A separate prognostic index has been developed for natural killer cell NHL (CNS-PINK) based on a cohort from the era of non-anthracycline-based chemotherapy with L-asparaginase [<a href="#rid72">72</a>]. CNS-PINK represents a combination of the prognostic index for systemic NK-cell NHL (stratified based on age &gt;60 years, stage III or IV disease, distant lymph node involvement, and nonnasal type disease) and number of extranodal sites. Patients with ≥2 extranodal sites and an intermediate or high PINK score had a cumulative CNS dissemination risk of 23 percent compared with 4 percent in the low-risk group (0 to 1 extranodal sites, low PINK score).</p><p class="headingAnchor" id="H14779484"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Patients with secondary involvement of the CNS from non-Hodgkin lymphoma (NHL) typically present relatively acutely, with neurologic symptoms emerging over days to weeks. Patients may present with a variety of signs and symptoms based upon the location of the disease within the CNS. In most cases, magnetic resonance imaging (MRI) will show abnormal enhancement within the leptomeninges, brain parenchyma, or spine, and cerebrospinal fluid (CSF) analysis can be diagnostic in cases of leptomeningeal involvement.</p><p class="headingAnchor" id="H7"><span class="h2">Leptomeningeal dissemination</span><span class="headingEndMark"> — </span>Leptomeningeal spread, or lymphomatous meningitis (LM), is a common nervous system complication of NHL, occurring in as many as 8 percent of patients with NHL [<a href="#rid16">16</a>].</p><p>LM typically presents within the first year of diagnosis of NHL. In a large review of NHL patients with CNS disease, a median duration of eight months passed between systemic disease and CNS infiltration [<a href="#rid1">1</a>]. Of the 20 patients with LM, 9 had LM as the initial manifestation of their disease.</p><p>Patients with LM commonly present with cranial nerve deficits, radicular pain, vague back or neck pain, mental status changes, focal weakness or sensory loss, or headache. Dysfunction at multiple levels of the neuraxis is common. Seizures are unusual but have been reported [<a href="#rid16">16,18,73</a>], possibly as a result of small tumor deposits causing cortical irritability. Patients may also present with neuroendocrine or behavioral syndromes, such as the syndrome of inappropriate antidiuretic hormone (SIADH) or hypothalamic dysfunction, due to infiltration of specific areas of the brain.</p><p>Cranial nerve palsy is among the most common finding, developing in up to 80 percent of patients [<a href="#rid16">16,17</a>]. One or several nerves may be affected, with a predilection for cranial nerves II, III, V, VI, and VII [<a href="#rid16">16,74</a>]. Hydrocephalus with nausea, vomiting, and papilledema may occur [<a href="#rid75">75</a>].</p><p>Because lymphoma cells in the subarachnoid space have easy access to every portion of the CNS, LM may present with a multitude of signs and symptoms [<a href="#rid76">76</a>], often lacking classical features of meningeal irritation such as neck rigidity or headache. For this reason, one must have a high index of suspicion for LM when evaluating lymphoma patients. As an example, one case report described hyperventilation as the initial manifestation of LM in a patient with a B cell lymphoma in leukemic phase [<a href="#rid77">77</a>].</p><p>Approximately one-quarter of patients with LM involvement will also have intraparenchymal brain lesions [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H14780143"><span class="h2">Parenchymal brain metastasis</span><span class="headingEndMark"> — </span>Parenchymal involvement of the brain by NHL has traditionally been considered distinctly less common than LM, although more contemporary series of patients with secondary CNS lymphoma indicate that the prevalence may be increasing.</p><p>In a large series of 592 patients with NHL published in 1980, only 1.4 percent developed cerebral dissemination, representing only 16 percent of the patients who developed CNS involvement of any sort [<a href="#rid1">1</a>]. By contrast, in a multicenter retrospective analysis by the International Primary Central Nervous System Lymphoma Study Group (IPCNSL) that included 92 patients diagnosed from 2000 to 2010 at five different centers, the most common site of CNS involvement was brain parenchyma (43 percent), followed by leptomeningeal (40 percent) and both parenchymal and leptomeningeal (8 percent) [<a href="#rid79">79</a>]. Other studies have reported a similar trend, with approximately 50 to 75 percent of patients having a parenchymal-only relapse [<a href="#rid24">24,25,80-83</a>].</p><p>Symptoms and signs depend on the number and location of brain dissemination. Presenting complaints include seizures, focal motor or sensory deficits, cranial nerve deficits, or depressed level of consciousness due to elevated intracranial pressure. (See  <a class="medical medical_review" href="/z/d/html/5217.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of brain metastases", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H14779758"><span class="h2">Spinal cord dissemination</span><span class="headingEndMark"> — </span>Intramedullary dissemination (IMD) may develop when a tumor in the subarachnoid space grows along nerve roots into the spinal cord or when there is direct hematogenous tumor spread [<a href="#rid84">84</a>]. IMD is sufficiently rare that its prevalence is difficult to estimate, and most patients with IMD present in the setting of widely disseminated disease [<a href="#rid85">85</a>].</p><p>In the largest published review of 79 cases of IMD, 6 (7.6 percent) were caused by malignant lymphoma. Lung cancer and breast cancer were the most common primary tumors reported to produce IMD [<a href="#rid86">86</a>]. Although classic neurologic teaching suggests that IMD is more likely than epidural metastases to present with a hemicord (Brown-Séquard) syndrome [<a href="#rid84">84</a>], this has only rarely been reported in the literature [<a href="#rid86">86</a>].</p><p>Typical presenting features of IMD include pain, weakness, spasticity, sensory loss, and bowel or bladder dysfunction. These symptoms and signs clearly point to spinal cord disease but are inadequate to distinguish between intramedullary and extramedullary processes [<a href="#rid86">86</a>]. Epidural spinal cord compression secondary to extension of a paraspinal or vertebral NHL mass is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma", section on 'Extranodal sites'</a>.)</p><p class="headingAnchor" id="H91239521"><span class="h2">Neurolymphomatosis</span><span class="headingEndMark"> — </span>Direct involvement of the peripheral nerves, typically the cranial nerves and spinal nerve roots, is an uncommon complication of NHL. It may occur either as a primary presentation, with or without other sites of systemic or CNS involvement, or as a relapse of prior systemic or primary CNS lymphoma (PCNSL) [<a href="#rid87">87-90</a>].</p><p>The majority of patients present with painful radiculopathy involving either cranial or spinal nerves, together with sensory or motor dysfunction involving one or more nerves. </p><p>Distinguishing neurolymphomatosis from a toxic or paraneoplastic neuropathy can be challenging in patients with a history of lymphoma and prior chemotherapy, and diagnosis often requires a high index of suspicion, multiple imaging techniques, and nerve biopsy. (See <a class="local">'Neuroimaging'</a> below and <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H6052480"><span class="h1">NEUROIMAGING</span><span class="headingEndMark"> — </span>Gadolinium-enhanced MRI is the most sensitive imaging technique for detection of CNS involvement from non-Hodgkin lymphoma (NHL). Patients with contraindications to MRI may be evaluated with contrast-enhanced cranial computed tomography.</p><p>The following findings may be seen on MRI of the brain or spinal cord:</p><p class="bulletIndent1"><span class="glyph">●</span>Enhancement and enlargement of one or more cranial nerves due to tumor infiltration is extremely suggestive of lymphomatous meningitis (LM)  (<a class="graphic graphic_diagnosticimage graphicRef69226" href="/z/d/graphic/69226.html" rel="external">image 1</a>). High-resolution contrast-enhanced skull base MRI can sometimes show cranial nerve abnormalities that are not seen on routine MRI. Fluid-attenuated inversion recovery (FLAIR) images may show hyperintensity within the subarachnoid space, indicative of high protein content.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Communicating hydrocephalus, leptomeningeal enhancement, or nerve root thickening are common yet less specific signs of LM  (<a class="graphic graphic_diagnosticimage graphicRef130161" href="/z/d/graphic/130161.html" rel="external">image 2</a> and <a class="graphic graphic_diagnosticimage graphicRef60419" href="/z/d/graphic/60419.html" rel="external">image 3</a> and <a class="graphic graphic_diagnosticimage graphicRef130163" href="/z/d/graphic/130163.html" rel="external">image 4</a> and <a class="graphic graphic_diagnosticimage graphicRef130166" href="/z/d/graphic/130166.html" rel="external">image 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parenchymal brain deposits from NHL appear as single or multiple contrast-enhancing lesions, often associated with surrounding edema  (<a class="graphic graphic_diagnosticimage graphicRef130167" href="/z/d/graphic/130167.html" rel="external">image 6</a>). In the immunocompetent host, the cellular lesions usually display homogeneously restricted water diffusion on apparent diffusion coefficient maps, distinguishing them from most primary brain tumors and solid-tumor metastases. Typical locations for NHL in the brain include the periventricular white matter and basal ganglia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spinal MRI in LM may show intradural enhancing nodules, especially at the level of the cauda equina; linear enhancement of the leptomeninges is a suggestive finding. Intramedullary spinal metastases appear as contrast-enhancing lesions within the spinal cord itself, often associated with surrounding edema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In neurolymphomatosis, MRI of the involved region shows thickening and enhancement of the nerve, plexus, or nerve root.</p><p></p><p>While positron emission tomography (PET) is generally not useful in the diagnosis of leptomeningeal or parenchymal brain lymphoma, it is indicated in the evaluation of neurolymphomatosis and may be more sensitive than MRI [<a href="#rid91">91</a>]. In such cases, PET may show increased uptake associated with an involved nerve plexus or at multiple levels along the spine within the exiting proximal nerve roots [<a href="#rid87">87,88,92</a>].</p><p class="headingAnchor" id="H6053884"><span class="h1">LUMBAR PUNCTURE</span><span class="headingEndMark"> — </span>The classic findings of lymphomatous meningitis (LM) on lumbar puncture (LP) and cerebrospinal fluid (CSF) analysis include a high opening pressure, low glucose concentration, high protein concentration, lymphocytic pleocytosis, and positive cytology and flow cytometry for malignant cells. Although most patients do not have all of these features, an entirely normal CSF examination is uncommon. In particular, the combination of a high protein concentration and lymphocytic pleocytosis is often found without other abnormalities. Radiographic evaluation with MRI of the brain and spine should be performed prior to LP or ventricular tap, although the MRI appearance of LP-induced intracranial hypotension (enhancement and thickening of the dura) is readily distinguishable from radiographic signs of LM.</p><p>The site of CSF sampling may affect the ability to detect LM [<a href="#rid93">93,94</a>]. Many patients with suspected LM have Ommaya reservoirs in place that allow for rapid, safe access to ventricular CSF. In one study in which CSF was concurrently sampled from ventricular and lumbar sites, there was a 32 percent discordance rate [<a href="#rid94">94</a>]. For patients with known radiographic disease involving the spinal cord or spinal nerve roots, the diagnostic yield of CSF obtained by LP was higher. Conversely, for patients with known intracranial leptomeningeal disease, the yield of CSF obtained via the Ommaya reservoir was higher. Accordingly, CSF sampling from both sites should be performed when feasible.</p><p>The CSF sample should be evaluated for cell counts, protein and glucose levels, cytology, flow cytometry, and immunoglobulin heavy chain (IgH) or T cell receptor gene rearrangement studies. Flow cytometry may detect cases of LM not found by cytology, and cytology may find cases not identified by flow cytometry [<a href="#rid95">95,96</a>].</p><p>A variety of molecules present in CSF have been studied as possible diagnostic markers for LM. Examples include beta2-microglobulin [<a href="#rid97">97</a>], D-dimer [<a href="#rid98">98</a>], soluble CD27 [<a href="#rid99">99</a>], and interleukin-10 [<a href="#rid100">100</a>]. None of these have proven adequately reliable or are validated for routine use. Other common but insensitive nonspecific laboratory findings include elevated CSF protein and decreased CSF glucose concentration [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H6054638"><span class="h2">CSF cytology</span><span class="headingEndMark"> — </span>Cytomorphologic examination by light microscopy of a cytospin preparation of CSF is the standard method for determining the presence of lymphoma cells in the CSF. However, false negatives and false positives can occur [<a href="#rid101">101,102</a>]. Because specificity of the technique is substantially greater than sensitivity, false-negative results are more common than false-positive results. A number of shortcomings of cytologic evaluation may preclude rapid diagnosis:</p><p class="bulletIndent1"><span class="glyph">●</span>The cell count in the CSF sample may be inadequate to permit positive identification of malignant cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infectious causes of atypical lymphocytosis (eg, viral illnesses, <em>Borrelia burgdorferi</em>) may lead to false-positive cytologic diagnoses [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cellular atypia is common in immunosuppressed patients, increasing diagnostic confusion [<a href="#rid104">104</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cytologic analysis requires fresh CSF and adequate preservation of cell structure [<a href="#rid102">102</a>].</p><p></p><p>Multiple LPs may be required in order to make the diagnosis of LM [<a href="#rid102">102</a>]. In a study of 15 patients with cytology-proven LM, a single LP was adequate for diagnosis in only 60 percent of cases. A second LP detected an additional 33 percent [<a href="#rid73">73</a>]. Other studies have demonstrated that serial LPs increase the sensitivity of CSF cytology for the diagnosis of LM [<a href="#rid105">105,106</a>]; accordingly, most authorities recommend two or three negative LPs when ruling out LM if suspected clinically.</p><p>Even when three CSF samples are obtained under optimal circumstances, countless retrospective and anecdotal reports in the literature confirm that cytologic diagnosis may be problematic. Specific guidelines for minimizing false-negative results are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5185.html" rel="external">"Clinical features and diagnosis of leptomeningeal disease from solid tumors", section on 'Cytology'</a>.)</p><p class="headingAnchor" id="H6054645"><span class="h2">Molecular techniques</span><span class="headingEndMark"> — </span>Molecular techniques including immunocytochemistry, flow cytometry, and polymerase chain reaction (PCR) can increase the sensitivity of CSF analysis for non-Hodgkin lymphoma (NHL) involvement.</p><p class="bulletIndent1"><span class="glyph">●</span>Immunocytochemistry uses a variety of monoclonal antibodies directed against known cell surface markers and is able to distinguish between lymphomatous and reactive cellular infiltrates. In such cases the immunophenotype of the abnormal CSF cells may be compared with that of the patient's primary tumor [<a href="#rid107">107</a>]. (See  <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma", section on 'Immunophenotype'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Flow cytometry is a related technique in which clonal populations of B lymphocytes are separated from reactive cells on the basis of size, granularity, and surface antigen expression  (<a class="graphic graphic_figure graphicRef67324" href="/z/d/graphic/67324.html" rel="external">figure 1</a>). Flow cytometry can detect populations of neoplastic cells comprising as few as 0.2 percent of CSF lymphocytes [<a href="#rid108">108,109</a>]. There is also a substantial improvement in sensitivity (43 to 50 percent) when flow cytometry is combined with conventional cytology [<a href="#rid95">95,96,108,110-112</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PCR relies on receptor gene rearrangement during B cell and T cell development to identify clonally related malignant cells  (<a class="graphic graphic_figure graphicRef81109" href="/z/d/graphic/81109.html" rel="external">figure 2</a>) [<a href="#rid113">113,114</a>]. As an example, in one study of patients with known CNS lymphoma, five of seven specimens suspicious but nondiagnostic by conventional cytology were positive by PCR [<a href="#rid113">113</a>]. Of 13 specimens that were negative by cytology, 5 were positive by PCR. In another study of patients with CSF involvement by NHL and non-neoplastic lymphoproliferative disorders affecting the CNS, sensitivity of CSF cytopathology, flow cytometry, and IgH gene rearrangement analysis were 27, 10, and 58 percent, respectively. Corresponding specificities were 100, 95, and 85 percent [<a href="#rid115">115</a>].</p><p></p><p class="bulletIndent1">A single-cell PCR technique designed to detect monoclonality on the basis of IgH gene rearrangement may be more sensitive and specific than standard PCR [<a href="#rid116">116</a>]. However, the primers utilized span only 70 percent of the potential sites of rearrangement; thus, a 30 percent false-negative rate exists [<a href="#rid117">117</a>]. Less experience exists with PCR detection of clonal T cell populations. Comparison of the PCR band size from the CSF with a PCR band from peripheral blood or a lymph node can reduce the false-positive rate.</p><p></p><p class="headingAnchor" id="H9"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Patients with non-Hodgkin lymphoma (NHL) presenting with neurologic signs or symptoms should undergo a complete history and physical examination. The history should pay specific attention to subtle symptoms suggestive of multifocal involvement of the CNS. A careful neurologic examination may reveal findings not suggested by the history.</p><p>MRI of the brain and spine should be performed in all patients suspected of having CNS disease. If a routine brain MRI is normal and clinical suspicion is high for leptomeningeal disease, a high-resolution brain MRI may highlight subtle enhancement of the cranial nerves not appreciated on routine sequences. (See <a class="local">'Neuroimaging'</a> above.)</p><p>Patients suspected of having lymphomatous meningitis (LM) as well as those with abnormal parenchymal enhancement suggestive of brain dissemination should undergo lumbar puncture (LP), unless there are contraindications to the procedure (see  <a class="medical medical_review" href="/z/d/html/4832.html" rel="external">"Lumbar puncture: Technique, contraindications, and complications in adults", section on 'Contraindications and precautions for high-risk patients'</a>). Cerebrospinal fluid (CSF) analysis should include cytology, flow cytometry, and polymerase chain reaction (PCR) to detect monoclonality on the basis of immunoglobulin heavy chain (IgH) or T cell receptor gene rearrangement. Patients with an Ommaya reservoir in place should have CSF samples collected from both the Ommaya reservoir (ie, ventricular tap) and lumbar space (ie, LP). (See <a class="local">'Lumbar puncture'</a> above.)</p><p>Radiographic evaluation with MRI of the brain and spine should be performed prior to LP or ventricular tap. (See  <a class="medical medical_review" href="/z/d/html/4832.html" rel="external">"Lumbar puncture: Technique, contraindications, and complications in adults"</a>.)</p><p>A complete assessment of systemic disease activity as summarized in the National Comprehensive Cancer Network (NCCN) guidelines for B cell and T cell lymphomas [<a href="#rid118">118,119</a>] is also indicated to facilitate treatment decisions and assist in prognosis. </p><p class="headingAnchor" id="H85679425"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>A diagnosis of CNS involvement from non-Hodgkin lymphoma (NHL) can be established in several ways:</p><p class="bulletIndent1"><span class="glyph">●</span>A positive cerebrospinal fluid (CSF) cytology establishes the diagnosis of lymphomatous meningitis (LM). Multiple lumbar punctures (LPs) may be required. (See <a class="local">'CSF cytology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical biopsy may be necessary to confirm the diagnosis of parenchymal brain dissemination [<a href="#rid120">120</a>] when CSF analysis is negative and radiographic findings are inconclusive, particularly in patients without a history of prior diffuse large B cell lymphoma (DLBCL) [<a href="#rid121">121</a>]. Imaging features of parenchymal NHL deposits characteristically display homogenous contrast enhancement and relative restriction of water diffusion; often there is infiltration along white matter tracts  (<a class="graphic graphic_diagnosticimage graphicRef130167" href="/z/d/graphic/130167.html" rel="external">image 6</a>). (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent1">Because treatment with corticosteroids may delay or interfere with diagnosis and alter imaging characteristics and histopathology of the tumor, it is important that they be avoided before neuroimaging and, if biopsy is indicated, until finalization of biopsy results. If necessary, patients with symptomatic edema or increased intracranial pressure can be initially treated with <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">mannitol</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For intramedullary spinal metastases, contrast-enhanced MRI in the appropriate clinical context establishes the diagnosis in most cases. CSF cytology will occasionally be confirmatory, particularly in patients with clinical or radiographic suspicion for concomitant leptomeningeal involvement. An open biopsy of the spinal cord is rarely indicated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A nerve biopsy is typically required for diagnosis of isolated neurolymphomatosis. CSF cytology is usually negative. In the appropriate clinical context (ie, a patient with a known history of NHL presenting with pain and neurologic deficits referable to multiple nerves), a characteristic pattern of nerve root thickening and enhancement or positron emission tomography (PET)-avid nerve roots may be sufficient.</p><p></p><p class="headingAnchor" id="H85679630"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>A variety of conditions can mimic the clinical presentation or MRI appearance of leptomeningeal dissemination from non-Hodgkin lymphoma (NHL), including infections, inflammatory processes, or late effects of prior therapy  (<a class="graphic graphic_table graphicRef53440" href="/z/d/graphic/53440.html" rel="external">table 3</a>). The differential diagnosis of leptomeningeal dissemination is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5185.html" rel="external">"Clinical features and diagnosis of leptomeningeal disease from solid tumors", section on 'Differential diagnosis'</a>.)</p><p>For patients presenting with a brain mass, the differential diagnosis includes other neoplasms as well as non-neoplastic entities such as vascular lesions or infection  (<a class="graphic graphic_table graphicRef64210" href="/z/d/graphic/64210.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/5180.html" rel="external">"Overview of the clinical features and diagnosis of brain tumors in adults", section on 'Neuroimaging features'</a>.)</p><p class="headingAnchor" id="H1782397"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic non-Hodgkin lymphoma (NHL) may involve the nervous system at every level, including peripheral nerve, spinal nerve root, spinal cord, meninges, and brain. Such involvement may include direct invasion or compression of these structures, as well as noninvasive paraneoplastic effects of NHL. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system (CNS) disease is found in a minority of patients at the time of NHL diagnosis, the exact percentage of which differs by histologic subtype. The majority of cases of CNS involvement by NHL occur in the setting of relapsed disease within the first year after completion of therapy. (See <a class="local">'Incidence and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leptomeningeal dissemination, or lymphomatous meningitis (LM), is the most common nervous system complication of NHL. Patients with LM commonly present with radicular pain, vague back or neck pain, mental status changes, cranial nerve deficits, focal weakness or sensory loss, or headache. Dysfunction at multiple levels of the neuraxis is common. (See <a class="local">'Leptomeningeal dissemination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parenchymal involvement of the brain by NHL has traditionally been considered distinctly less common than LM, although the prevalence may be increasing. Presenting complaints include seizures, focal motor or sensory deficits, cranial nerve deficits, or depressed level of consciousness due to elevated intracranial pressure. (See <a class="local">'Parenchymal brain metastasis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intramedullary spinal dissemination (IMD) is a rare manifestation of secondary CNS lymphoma that may develop when a tumor in the subarachnoid space grows along nerve roots into the spinal cord or when there is direct hematogenous tumor spread. (See <a class="local">'Spinal cord dissemination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gadolinium-enhanced MRI is the most sensitive imaging technique for detection of CNS involvement from NHL. All patients with suspected CNS disease should undergo brain and spine MRI prior to lumbar puncture (LP). (See <a class="local">'Neuroimaging'</a> above and <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of lymphomatous meningitis (LM) is made based upon the pathologic evaluation of a sample of cerebrospinal fluid (CSF) interpreted within the clinical context. The CSF sample should be evaluated for cell counts, protein and glucose levels, cytology, flow cytometry, and immunoglobulin heavy chain (IgH) or T cell receptor gene rearrangement studies. Flow cytometry may detect cases of LM not found by cytology, and cytology may find cases not identified by flow cytometry. (See <a class="local">'Lumbar puncture'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NHL lesions are distinguished from other neoplasms and infectious, inflammatory, or metabolic causes by homogenous contrast enhancement, relative restriction of water diffusion, infiltrative appearance, and characteristic location. Surgical biopsy may be necessary to confirm the diagnosis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The differential diagnosis includes a variety of conditions that can mimic the clinical presentation or MRI patterns seen in patients with suspected LM from NHL, such as infections, inflammatory processes, late effects of prior therapy, and imaging artifacts. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H2144157246"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Andrew Norden, MD, and Ephraim Hochberg, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Levitt LJ, Dawson DM, Rosenthal DS, Moloney WC. CNS involvement in the non-Hodgkin's lymphomas. Cancer 1980; 45:545.</a></li><li><a class="nounderline abstract_t">Gleissner B, Chamberlain M. Treatment of CNS dissemination in systemic lymphoma. J Neurooncol 2007; 84:107.</a></li><li><a class="nounderline abstract_t">Bernstein SH, Unger JM, Leblanc M, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. J Clin Oncol 2009; 27:114.</a></li><li><a class="nounderline abstract_t">Lossos A, Ashhab Y, Sverdlin E, et al. Late-delayed cerebral involvement in systemic non-Hodgkin lymphoma: a second primary tumor or a tardy recurrence? Cancer 2004; 101:1843.</a></li><li><a class="nounderline abstract_t">Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 1989; 169:2233.</a></li><li><a class="nounderline abstract_t">Kern WF, Spier CM, Hanneman EH, et al. Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. Blood 1992; 79:2432.</a></li><li><a class="nounderline abstract_t">Engelhardt B, Martin-Simonet MT, Rott LS, et al. Adhesion molecule phenotype of T lymphocytes in inflamed CNS. J Neuroimmunol 1998; 84:92.</a></li><li><a class="nounderline abstract_t">Kivisäkk P, Mahad DJ, Callahan MK, et al. Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A 2003; 100:8389.</a></li><li><a class="nounderline abstract_t">Anthony IC, Crawford DH, Bell JE. B lymphocytes in the normal brain: contrasts with HIV-associated lymphoid infiltrates and lymphomas. Brain 2003; 126:1058.</a></li><li><a class="nounderline abstract_t">Smith JR, Braziel RM, Paoletti S, et al. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 2003; 101:815.</a></li><li><a class="nounderline abstract_t">Jahnke K, Hummel M, Korfel A, et al. Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J Clin Oncol 2006; 24:4754.</a></li><li><a class="nounderline abstract_t">Vater I, Montesinos-Rongen M, Schlesner M, et al. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia 2015; 29:677.</a></li><li><a class="nounderline abstract_t">Montesinos-Rongen M, Terrao M, May C, et al. The process of somatic hypermutation increases polyreactivity for central nervous system antigens in primary central nervous system lymphoma. Haematologica 2021; 106:708.</a></li><li><a class="nounderline abstract_t">Thurner L, Preuss KD, Bewarder M, et al. Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma. Blood 2018; 132:2744.</a></li><li><a class="nounderline abstract_t">El-Galaly TC, Cheah CY, Bendtsen MD, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 2018; 93:57.</a></li><li><a class="nounderline abstract_t">Mead GM, Kennedy P, Smith JL, et al. Involvement of the central nervous system by non-Hodgkin's lymphoma in adults. A review of 36 cases. Q J Med 1986; 60:699.</a></li><li><a class="nounderline abstract_t">Hoerni-Simon G, Suchaud JP, Eghbali H, et al. Secondary involvement of the central nervous system in malignant non-Hodgkin's lymphoma. A study of 30 cases in a series of 498 patients. Oncology 1987; 44:98.</a></li><li><a class="nounderline abstract_t">Zinzani PL, Magagnoli M, Frezza G, et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: The Bologna experience. Leuk Lymphoma 1999; 32:571.</a></li><li><a class="nounderline abstract_t">Hollender A, Kvaloy S, Lote K, et al. Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer 2000; 36:1762.</a></li><li><a class="nounderline abstract_t">Hollender A, Kvaloy S, Nome O, et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: A risk model. Ann Oncol 2002; 13:1099.</a></li><li><a class="nounderline abstract_t">van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998; 91:1178.</a></li><li><a class="nounderline abstract_t">Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--A survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007; 18:149.</a></li><li><a class="nounderline abstract_t">Evens AM, Danilov A, Jagadeesh D, et al. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood 2021; 137:374.</a></li><li><a class="nounderline abstract_t">Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: An analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009; 113:3896.</a></li><li><a class="nounderline abstract_t">Villa D, Connors JM, Shenkier TN, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010; 21:1046.</a></li><li><a class="nounderline abstract_t">Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggressive B-cell lymphoma: An analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 2012; 23:1267.</a></li><li><a class="nounderline abstract_t">Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol 2011; 90:809.</a></li><li><a class="nounderline abstract_t">Yamamoto W, Tomita N, Watanabe R, et al. Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol 2010; 85:6.</a></li><li><a class="nounderline abstract_t">Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006; 20:319.</a></li><li><a class="nounderline abstract_t">Oinonen R, Franssila K, Elonen E. Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol 1999; 78:145.</a></li><li><a class="nounderline abstract_t">Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: Influence of rituximab. Ann Oncol 2004; 15:129.</a></li><li><a class="nounderline abstract_t">Pro B, Perini G. Central nervous system prophylaxis in peripheral T-cell lymphoma. Blood 2010; 115:5427.</a></li><li><a class="nounderline abstract_t">Chihara D, Fanale MA, Miranda RN, et al. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One 2018; 13:e0191461.</a></li><li><a class="nounderline abstract_t">Yi JH, Kim JH, Baek KK, et al. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma. Ann Oncol 2011; 22:1636.</a></li><li><a class="nounderline abstract_t">Rappaport H, Thomas LB. Mycosis fungoides: the pathology of extracutaneous involvement. Cancer 1974; 34:1198.</a></li><li><a class="nounderline abstract_t">Hallahan D, Griem M, Griem S, et al. Mycosis fungoides involving the central nervous system. J Clin Oncol 1986; 4:1638.</a></li><li><a class="nounderline abstract_t">Fonseca R, Habermann TM, Colgan JP, et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer 2000; 88:154.</a></li><li><a class="nounderline abstract_t">Björkholm M, Hagberg H, Holte H, et al. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol 2007; 18:1085.</a></li><li><a class="nounderline abstract_t">Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol Oncol 1990; 8:141.</a></li><li><a class="nounderline abstract_t">MacKintosh FR, Colby TV, Podolsky WJ, et al. Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer 1982; 49:586.</a></li><li><a class="nounderline abstract_t">McMillan A. Central nervous system-directed preventative therapy in adults with lymphoma. Br J Haematol 2005; 131:13.</a></li><li><a class="nounderline abstract_t">Bos GM, van Putten WL, van der Holt B, et al. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Ann Oncol 1998; 9:191.</a></li><li><a class="nounderline abstract_t">Keldsen N, Michalski W, Bentzen SM, et al. Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis. Acta Oncol 1996; 35:703.</a></li><li><a class="nounderline abstract_t">Mannisto S, Vähämurto P, Pollari M, et al. Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma. Eur J Cancer 2019; 115:27.</a></li><li><a class="nounderline abstract_t">Kohn M, Karras A, Zaidan M, et al. Lymphomas with kidney involvement: the French multicenter retrospective LyKID study. Leuk Lymphoma 2020; 61:887.</a></li><li><a class="nounderline abstract_t">Au WY, Chan AC, Chow LW, Liang R. Lymphoma of the breast in Hong Kong Chinese. Hematol Oncol 1997; 15:33.</a></li><li><a class="nounderline abstract_t">Yamazaki H, Hanada M, Kitada M, et al. Four cases of central nervous system involvement of breast malignant lymphoma. Jpn J Clin Oncol 2003; 33:399.</a></li><li><a class="nounderline abstract_t">Ribrag V, Bibeau F, El Weshi A, et al. Primary breast lymphoma: a report of 20 cases. Br J Haematol 2001; 115:253.</a></li><li><a class="nounderline abstract_t">Ludmir EB, Milgrom SA, Pinnix CC, et al. Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure&lt;sup/&gt;. Leuk Lymphoma 2018; 59:2896.</a></li><li><a class="nounderline abstract_t">Tomita N, Yokoyama M, Yamamoto W, et al. The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis. Leuk Lymphoma 2018; 59:97.</a></li><li><a class="nounderline abstract_t">Bishop PC, Wilson WH, Pearson D, et al. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 1999; 17:2479.</a></li><li><a class="nounderline abstract_t">Gholam D, Bibeau F, El Weshi A, et al. Primary breast lymphoma. Leuk Lymphoma 2003; 44:1173.</a></li><li><a class="nounderline abstract_t">Kuper-Hommel MJ, Snijder S, Janssen-Heijnen ML, et al. Treatment and survival of 38 female breast lymphomas: a population-based study with clinical and pathological reviews. Ann Hematol 2003; 82:397.</a></li><li><a class="nounderline abstract_t">Wong WW, Schild SE, Halyard MY, Schomberg PJ. Primary non-Hodgkin lymphoma of the breast: The Mayo Clinic Experience. J Surg Oncol 2002; 80:19.</a></li><li><a class="nounderline abstract_t">Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 2008; 19:233.</a></li><li><a class="nounderline abstract_t">Bekkenk MW, Postma TJ, Meijer CJ, Willemze R. Frequency of central nervous system involvement in primary cutaneous B-cell lymphoma. Cancer 2000; 89:913.</a></li><li><a class="nounderline abstract_t">Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 2014; 166:891.</a></li><li><a class="nounderline abstract_t">Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood 2016; 127:2182.</a></li><li><a class="nounderline abstract_t">Klanova M, Sehn LH, Bence-Bruckler I, et al. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood 2019; 133:919.</a></li><li><a class="nounderline abstract_t">Ollila TA, Kurt H, Waroich J, et al. Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma. Blood 2021; 137:1120.</a></li><li><a class="nounderline abstract_t">Wright GW, Huang DW, Phelan JD, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell 2020; 37:551.</a></li><li><a class="nounderline abstract_t">El-Galaly TC, Villa D, Michaelsen TY, et al. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer 2017; 75:195.</a></li><li><a class="nounderline abstract_t">Savage KJ, Zeynalova S, Kansara RR, et al. Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. Blood 2014; 124:394 (abstract).</a></li><li><a class="nounderline abstract_t">Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index: A risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2016; 34:3150.</a></li><li><a class="nounderline abstract_t">Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003; 21:20.</a></li><li><a class="nounderline abstract_t">Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: Final results of an international phase II trial. J Clin Oncol 2011; 29:2766.</a></li><li><a class="nounderline abstract_t">Villa D, Connors JM, Sehn LH, et al. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica 2011; 96:1002.</a></li><li><a class="nounderline abstract_t">Jia Y, Sun C, Liu Z, et al. Primary breast diffuse large B-cell lymphoma: A population-based study from 1975 to 2014. Oncotarget 2018; 9:3956.</a></li><li><a class="nounderline abstract_t">Hosein PJ, Maragulia JC, Salzberg MP, et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol 2014; 165:358.</a></li><li><a class="nounderline abstract_t">McMillan A, Ardeshna KM, Cwynarski K, et al. Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. Br J Haematol 2013; 163:168.</a></li><li><a class="nounderline abstract_t">Shimada K, Murase T, Matsue K, et al. Central nervous system involvement in intravascular large B-cell lymphoma: A retrospective analysis of 109 patients. Cancer Sci 2010; 101:1480.</a></li><li><a class="nounderline abstract_t">Kim H, Jeong H, Yamaguchi M, et al. Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood 2020; 136:2548.</a></li><li><a class="nounderline abstract_t">Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990; 9:225.</a></li><li><a class="nounderline abstract_t">Yoshida S, Morii K, Watanabe M, Saito T. Characteristic features of malignant lymphoma with central nervous system involvement. Surg Neurol 2000; 53:163.</a></li><li><a class="nounderline abstract_t">Allen C, Bell J, McNaughton H, Warlow C. Papilloedema and lymphocytic meningitis in a 68 year old man. J Neurol Neurosurg Psychiatry 1995; 58:374.</a></li><li><a class="nounderline abstract_t">DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998; 38:245.</a></li><li><a class="nounderline abstract_t">Karp G, Nahum K. Hyperventilation as the initial manifestation of lymphomatous meningitis. J Neurooncol 1992; 13:173.</a></li><li><a class="nounderline abstract_t">Ferreri AJ, Assanelli A, Crocchiolo R, Ciceri F. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. Hematol Oncol 2009; 27:61.</a></li><li><a class="nounderline abstract_t">Bromberg JE, Doorduijn JK, Illerhaus G, et al. Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--An International Primary Central Nervous System Lymphoma Study Group project. Haematologica 2013; 98:808.</a></li><li><a class="nounderline abstract_t">Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 2009; 89:577.</a></li><li><a class="nounderline abstract_t">Kumar A, Vanderplas A, LaCasce AS, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer 2012; 118:2944.</a></li><li><a class="nounderline abstract_t">Guirguis HR, Cheung MC, Mahrous M, et al. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol 2012; 159:39.</a></li><li><a class="nounderline abstract_t">Tomita N, Yokoyama M, Yamamoto W, et al. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2012; 103:245.</a></li><li class="breakAll">Schiff D, Wen P. Nervous system metastases. In: Neurology in Clinical Practice, Walter GB, Daroff RB, Fenichel GM, Jankovic J (Eds), Butterworth Heinemann, Philadelphia 2004. p.1441.</li><li class="breakAll">DeAngelis LM, Posner JB. Neurologic Complications of Cancer, 2nd ed, Oxford University Press, New York 2009.</li><li><a class="nounderline abstract_t">Edelson RN, Deck MD, Posner JB. Intramedullary spinal cord metastases. Clinical and radiographic findings in nine cases. Neurology 1972; 22:1222.</a></li><li><a class="nounderline abstract_t">Grisariu S, Avni B, Batchelor TT, et al. Neurolymphomatosis: An International Primary CNS Lymphoma Collaborative Group report. Blood 2010; 115:5005.</a></li><li><a class="nounderline abstract_t">Tomita M, Koike H, Kawagashira Y, et al. Clinicopathological features of neuropathy associated with lymphoma. Brain 2013; 136:2563.</a></li><li><a class="nounderline abstract_t">Baehring JM, Damek D, Martin EC, et al. Neurolymphomatosis. Neuro Oncol 2003; 5:104.</a></li><li><a class="nounderline abstract_t">Ducatel P, Michaud M, Viala K, et al. Neurolymphomatosis: involvement of peripheral nervous system revealing hematologic malignancy, a report of nine cases. J Peripher Nerv Syst 2023; 28:252.</a></li><li><a class="nounderline abstract_t">Salm LP, Van der Hiel B, Stokkel MP. Increasing importance of 18F-FDG PET in the diagnosis of neurolymphomatosis. Nucl Med Commun 2012; 33:907.</a></li><li><a class="nounderline abstract_t">Davidson T, Kedmi M, Avigdor A, et al. FDG PET-CT evaluation in neurolymphomatosis: imaging characteristics and clinical outcomes. Leuk Lymphoma 2018; 59:348.</a></li><li><a class="nounderline abstract_t">Schiff D, Feske SK, Wen PY. Deceptively normal ventricular fluid in lymphomatous meningitis. Arch Intern Med 1993; 153:389.</a></li><li><a class="nounderline abstract_t">Chamberlain MC, Kormanik PA, Glantz MJ. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro Oncol 2001; 3:42.</a></li><li><a class="nounderline abstract_t">Finn WG, Peterson LC, James C, Goolsby CL. Enhanced detection of malignant lymphoma in cerebrospinal fluid by multiparameter flow cytometry. Am J Clin Pathol 1998; 110:341.</a></li><li><a class="nounderline abstract_t">Bromberg JE, Breems DA, Kraan J, et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology 2007; 68:1674.</a></li><li><a class="nounderline abstract_t">Jeffery GM, Frampton CM, Legge HM, Hart DN. Cerebrospinal fluid B2-microglobulin levels in meningeal involvement by malignancy. Pathology 1990; 22:20.</a></li><li><a class="nounderline abstract_t">Eclache V, Vu T, Le Roux G. D-dimer levels in the cerebrospinal fluid: a marker of central nervous system involvement in neoplastic disease. Nouv Rev Fr Hematol 1994; 36:321.</a></li><li><a class="nounderline abstract_t">van den Bent MJ, Lamers CH, van 't Veer MB, et al. Increased levels of soluble CD27 in the cerebrospinal fluid are not diagnostic for leptomeningeal involvement by lymphoid malignancies. Ann Hematol 2002; 81:187.</a></li><li><a class="nounderline abstract_t">Wang L, Luo L, Gao Z, et al. The diagnostic and prognostic value of interleukin-10 in cerebrospinal fluid for central nervous system lymphoma: A meta-analysis. Leuk Lymphoma 2017; 58:2452.</a></li><li><a class="nounderline abstract_t">Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979; 29:1369.</a></li><li><a class="nounderline abstract_t">Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998; 82:733.</a></li><li><a class="nounderline abstract_t">García-Moncó JC, Gómez Beldarrain M, Benach JL, et al. Borrelia meningitis mimicking meningeal lymphoma. Neurology 1994; 44:2207.</a></li><li><a class="nounderline abstract_t">Bigner SH. Cerebrospinal fluid (CSF) cytology: current status and diagnostic applications. J Neuropathol Exp Neurol 1992; 51:235.</a></li><li><a class="nounderline abstract_t">Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995; 38:51.</a></li><li><a class="nounderline abstract_t">Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients. Cancer 1982; 49:759.</a></li><li><a class="nounderline abstract_t">Tani E, Costa I, Svedmyr E, Skoog L. Diagnosis of lymphoma, leukemia, and metastatic tumor involvement of the cerebrospinal fluid by cytology and immunocytochemistry. Diagn Cytopathol 1995; 12:14.</a></li><li><a class="nounderline abstract_t">Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005; 105:496.</a></li><li><a class="nounderline abstract_t">Quijano S, López A, Manuel Sancho J, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol 2009; 27:1462.</a></li><li><a class="nounderline abstract_t">French CA, Dorfman DM, Shaheen G, Cibas ES. Diagnosing lymphoproliferative disorders involving the cerebrospinal fluid: increased sensitivity using flow cytometric analysis. Diagn Cytopathol 2000; 23:369.</a></li><li><a class="nounderline abstract_t">Roma AA, Garcia A, Avagnina A, et al. Lymphoid and myeloid neoplasms involving cerebrospinal fluid: comparison of morphologic examination and immunophenotyping by flow cytometry. Diagn Cytopathol 2002; 27:271.</a></li><li><a class="nounderline abstract_t">Benevolo G, Stacchini A, Spina M, et al. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood 2012; 120:3222.</a></li><li><a class="nounderline abstract_t">Rhodes CH, Glantz MJ, Glantz L, et al. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer 1996; 77:543.</a></li><li><a class="nounderline abstract_t">Gleissner B, Siehl J, Korfel A, et al. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 2002; 58:390.</a></li><li><a class="nounderline abstract_t">Baehring JM, Hochberg FH, Betensky RA, et al. Immunoglobulin gene rearrangement analysis in cerebrospinal fluid of patients with lymphoproliferative processes. J Neurol Sci 2006; 247:208.</a></li><li><a class="nounderline abstract_t">Hug A, Storch-Hagenlocher B, Haas J, et al. Single-cell PCR analysis of the immunoglobulin heavy-chain CDR3 region for the diagnosis of leptomeningeal involvement of B-cell malignancies using standard cerebrospinal fluid cytospins. J Neurol Sci 2004; 219:83.</a></li><li><a class="nounderline abstract_t">Gong JZ, Zheng S, Chiarle R, et al. Detection of immunoglobulin kappa light chain rearrangements by polymerase chain reaction. An improved method for detecting clonal B-cell lymphoproliferative disorders. Am J Pathol 1999; 155:355.</a></li><li class="breakAll">B-cell lymphomas. National Comprehensive Cancer Network. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1480 (Accessed on April 08, 2022).</li><li class="breakAll">T-cell lymphomas. National Comprehensive Cancer Network. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1483 (Accessed on April 08, 2022).</li><li class="breakAll">Giglio P, Gilbert MR. Neurological complications of non-Hodgkin's lymphoma. In: Lymphoma of the Nervous System, Batchelor TT (Ed), Butterworth Heinemann, Amsterdam 2004. p.107.</li><li><a class="nounderline abstract_t">Brown DA, Goyal A, Richter KR, et al. Clinical utility of brain biopsy for presumed CNS relapse of systemic lymphoma. J Neurosurg 2022; 136:30.</a></li></ol></div><div id="topicVersionRevision">Topic 4720 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6986199" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : CNS involvement in the non-Hodgkin's lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17332946" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of CNS dissemination in systemic lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047289" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15372481" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Late-delayed cerebral involvement in systemic non-Hodgkin lymphoma: a second primary tumor or a tardy recurrence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2471777" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1373974" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9600713" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Adhesion molecule phenotype of T lymphocytes in inflamed CNS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12829791" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12690046" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : B lymphocytes in the normal brain: contrasts with HIV-associated lymphoid infiltrates and lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393412" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16966685" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25189415" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32193251" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The process of somatic hypermutation increases polyreactivity for central nervous system antigens in primary central nervous system lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30249786" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29477102" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3763820" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Involvement of the central nervous system by non-Hodgkin's lymphoma in adults. A review of 36 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3574856" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Secondary involvement of the central nervous system in malignant non-Hodgkin's lymphoma. A study of 30 cases in a series of 498 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10048430" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10974623" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12176790" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9454747" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17018708" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32663292" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19144985" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19861575" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21989328" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21229246" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20236301" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Central nervous system involvement in diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16884838" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : CNS prophylaxis in lymphoma: who to target and what therapy to use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10211757" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Central nervous system involvement in patients with mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14679132" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20595522" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Central nervous system prophylaxis in peripheral T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29538376" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The risk of central nervous system relapses in patients with peripheral T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21220520" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4424204" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mycosis fungoides: the pathology of extracutaneous involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3772417" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mycosis fungoides involving the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10618618" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Testicular lymphoma is associated with a high incidence of extranodal recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17363838" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2373491" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7059915" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16173958" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Central nervous system-directed preventative therapy in adults with lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9553665" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8938217" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31082690" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32037948" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lymphomas with kidney involvement: the French multicenter retrospective LyKID study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9378471" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Lymphoma of the breast in Hong Kong Chinese.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14523060" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Four cases of central nervous system involvement of breast malignant lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11703318" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Primary breast lymphoma: a report of 20 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29697005" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure&lt;sup/&gt;.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28593796" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561312" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : CNS involvement in primary mediastinal large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12916870" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Primary breast lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12764549" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Treatment and survival of 38 female breast lymphomas: a population-based study with clinical and pathological reviews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11967901" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Primary non-Hodgkin lymphoma of the breast: The Mayo Clinic Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17932394" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10951357" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Frequency of central nervous system involvement in primary cutaneous B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24943107" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Double hit lymphoma: the MD Anderson Cancer Center clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26834242" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30617197" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32877514" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32289277" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28237865" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27382100" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12506165" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21646602" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21486867" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29423097" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Primary breast diffuse large B-cell lymphoma: a population-based study from 1975 to 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24467658" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24033102" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20412122" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32584959" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2086737" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10713195" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Characteristic features of malignant lymphoma with central nervous system involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7897426" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Papilloedema and lymphocytic meningitis in a 68 year old man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9696379" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Current diagnosis and treatment of leptomeningeal metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1279132" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Hyperventilation as the initial manifestation of lymphomatous meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19247977" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23144196" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19353238" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22006274" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22849793" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22044593" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22044593" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22044593" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4346871" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Intramedullary spinal cord metastases. Clinical and radiographic findings in nine cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20368468" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23884813" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Clinicopathological features of neuropathy associated with lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12672282" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Neurolymphomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36861226" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Neurolymphomatosis: involvement of peripheral nervous system revealing hematologic malignancy, a report of nine cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22714006" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Increasing importance of 18F-FDG PET in the diagnosis of neurolymphomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28750592" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : FDG PET-CT evaluation in neurolymphomatosis: imaging characteristics and clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8427541" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Deceptively normal ventricular fluid in lymphomatous meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11305416" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9728609" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Enhanced detection of malignant lymphoma in cerebrospinal fluid by multiparameter flow cytometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502548" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2194155" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Cerebrospinal fluid B2-microglobulin levels in meningeal involvement by malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7971253" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : D-dimer levels in the cerebrospinal fluid: a marker of central nervous system involvement in neoplastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11976819" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Increased levels of soluble CD27 in the cerebrospinal fluid are not diagnostic for leptomeningeal involvement by lymphoid malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28278715" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The diagnostic and prognostic value of interleukin-10 in cerebrospinal fluid for central nervous system lymphoma: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/573381" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9477107" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7969989" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Borrelia meningitis mimicking meningeal lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1583530" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Cerebrospinal fluid (CSF) cytology: current status and diagnostic applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7611725" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6895713" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7789240" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Diagnosis of lymphoma, leukemia, and metastatic tumor involvement of the cerebrospinal fluid by cytology and immunocytochemistry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15358629" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19224854" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11074639" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Diagnosing lymphoproliferative disorders involving the cerebrospinal fluid: increased sensitivity using flow cytometric analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12411991" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Lymphoid and myeloid neoplasms involving cerebrospinal fluid: comparison of morphologic examination and immunophenotyping by flow cytometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22927246" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630963" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11839837" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16764890" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Immunoglobulin gene rearrangement analysis in cerebrospinal fluid of patients with lymphoproliferative processes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15050442" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Single-cell PCR analysis of the immunoglobulin heavy-chain CDR3 region for the diagnosis of leptomeningeal involvement of B-cell malignancies using standard cerebrospinal fluid cytospins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10433929" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Detection of immunoglobulin kappa light chain rearrangements by polymerase chain reaction. An improved method for detecting clonal B-cell lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10433929" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Detection of immunoglobulin kappa light chain rearrangements by polymerase chain reaction. An improved method for detecting clonal B-cell lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10433929" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Detection of immunoglobulin kappa light chain rearrangements by polymerase chain reaction. An improved method for detecting clonal B-cell lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10433929" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Detection of immunoglobulin kappa light chain rearrangements by polymerase chain reaction. An improved method for detecting clonal B-cell lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34214988" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Clinical utility of brain biopsy for presumed CNS relapse of systemic lymphoma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
